Author

N. Bayani

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. Balmain· 2 shared Q. Tran· 2 shared R. Delrosario· 2 shared A. Goga· 1 shared D. Wu· 1 shared E. Kandyba· 1 shared E. N. Bergstrom· 1 shared H. J. Donnella· 1 shared

Activity by Year

2017-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Balmain

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The interplay between dormant mutated cells and tumor promotion by chronic tissue damage in determining cancer risk.

Y. R. Li, E. Kandyba, K. Halliwill, R. Delrosario, Q. Tran, N. Bayani, D. Wu, O. Mirzoeva, M. M. Reeves, M. Islam, L. Riva, E. N. Bergstrom, K. Achanta, J. Digiovanni, L. Alexandrov, A. Balmain

This study analyzes mouse skin tumors to determine how environmental factors like TPA, obesity, and wounding affect mutational burden and cancer risk, finding that tumor promoters, not mutation number, limit tumor growth.

bioRxiv · Jan 24, 2024 · PreprintCancer Biology

Regulation of KRAS4A/B splicing in cancer stem cells by the RBM39 splicing complex.

W.-C. Chen, M. D. To, P. M. K. Westcott, R. Delrosario, I.-J. Kim, M. Phillips, Q. Tran, N. Bayani, A. Balmain

This study identifies KRAS4A and KRAS4B splice isoforms with distinct expression patterns in cancer stem cells and shows that targeting KRAS4A splicing is a potential therapeutic strategy in KRAS mutant tumors.

bioRxiv · May 22, 2019 · PreprintCancer Biology

Kinome rewiring reveals AURKA is a molecular barrier to the efficacy of PI3K/mTOR-pathway inhibitors in breast cancer

H. J. Donnella, J. T. Webber, R. S. Levin, R. Camarda, O. Momcilovic, N. Bayani, K. N. Shah, J. Korkola, K. M. Shokat, A. Goga, J. Gordan, S. Bandyopadhyay

The paper identifies AURKA as a barrier to PI3K/mTOR inhibitor efficacy in breast cancer by mapping kinome dynamics and showing that AURKA inhibition synergizes with these drugs to induce apoptosis and tumor regression.

bioRxiv · Jun 30, 2017Cancer Biology